Details of the Drug Reposition

General Information of This Drug (ID: DM5XUQL)

• Drug Name: CPI-613 (DM5XUQL)
• Synonyms: CPI-613; 95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

2 Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Acute myeloid leukaemia	DIS0BM1I	2A60	Phase 3	[1]
Pancreatic cancer	DISJC981	2C10	Phase 3	[2]

3 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Myelodysplastic syndrome	DISYHNUI	2A37	Phase 2	[1]
Recurrent adult burkitt lymphoma	DIS6V60A	2A85.6	Phase 2	[3]
B-cell lymphoma	DISIH1YQ	2A86	Phase 2	[3]

2 Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
T-cell lymphoma	DISSXRTQ	2A90	Phase 1	[3]
Metastatic colorectal cancer	DIS18R3K	2B91	Phase 1	[3]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] ClinicalTrials.gov (NCT03504423) Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas. U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)